Skip to main content
Premium Trial:

Request an Annual Quote

Cristopher McReynolds, Ferdinand Verdonck, Harrold van Barlingen, Russell Bradley, Gregory Gosch, and Randel Marfin


Cristopher McReynolds joined Galapagos of Belgium last month as director of business development for Galapagos and its subsidiary Galadeno in the US, GenomeWeb News, a CBA News sister publication learned last week. Most recently, he was vice president of business development at Cepheid. McReynolds holds and MBA and a BSc in biology and zoology.

In addition, Ferdinand Verdonck has become an independent director, and Harrold van Barlingen a dependent director of Galapagos, the company said on Monday. Four other directors, Ronald Brus, Stephen Bunting, Steven Burrill, and Dirk Pollet, stepped down from the board.

Verdonck was most recently managing director of Almanij. He holds a law degree and an economics degree from the University of Leuven in Belgium and a degree in economics from the University of Chicago. Barlingen heads life science investments at AlpInvest Partners. He holds a PhD in cardiovascular diseases and an MSc in medical biology from the University of Utrecht in the Netherlands.

The board changes result from Galapagos' listing on the Euronext stock exchange, according to the company.

Russell Bradley has become vice president of business development and strategic planning of Luminex, the Austin, Texas-based company said on Monday. In addition, Gregory Gosch has become vice president of marketing and sales, and Randel Marfin vice president of the Luminex Bioscience Group, a new position.

Most recently, Bradley was director of Beckman Coulter's Cares Initiative. He holds a bachelor of science degree in immunology and biochemistry from Monash University in Australia.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.